David Saber, MBA
Mr. Saber has over 17 years of experience in corporate development, business development, alliance management and strategic planning roles in specialty and generic pharmaceutical businesses. He joined Mirubi Group as Managing Director in 2014.
Previously, Dave served as VP – Corporate Development for Handa Pharmaceuticals, where he advised the CEO on corporate and portfolio strategy, internal controls, and investor relations. Responsibilities included product evaluation, opportunity forecasting, asset valuation and M&A due diligence. During his tenure, Dave helped Handa redirect its drug delivery and patent expertise toward innovative specialty brand opportunities.
Other previous roles include Senior Director, Business Development at Par Pharmaceutical (now Endo), where he led the generic BD team, successfully negotiating and / or overseeing several dozen collaboration, acquisition and divestiture deals. Prior to joining Par, Dave served as Director of Strategic Planning at Taro Pharmaceuticals, where he led the interdisciplinary portfolio strategy and product evaluation process.
Dave has been a featured speaker at several pharmaceutical industry conferences, most recently as Co-Chair of Marcus Evans’ 11th Product Selection & Pipeline Optimization for Generics conference, in September 2018.